Independent. No paid placement. Reviewed weekly Editorial policy Newsletter

Home›The Library›Darbepoetin alfa

Darbepoetin Alfa

Written by The Peptide Record editorialClinical review not yet completedLast reviewed 19 September 2026

Darbepoetin alfa (Aranesp) is a real, FDA-approved longer-acting analog of erythropoietin, engineered with extra sugar chains for a longer half-life than epoetin alfa — subject to the same 2007 class-wide boxed warning, and its own large trial (TREAT) later found it doubled stroke risk without a compensating cardiovascular or survival benefit.

On this page
  1. Hyperglycosylated for a longer half-life
  2. The TREAT trial
  3. Current status

In brief

Should you care? Relevant if you or someone you know is managing anemia from chronic kidney disease or chemotherapy, especially if considering darbepoetin specifically over epoetin alfa.

The short version

  • The same erythropoietin backbone as epoetin alfa, engineered with extra sugar chains for a longer half-life and less frequent dosing.
  • Approved 2001; carries the identical 2007 class-wide boxed warning as epoetin alfa.
  • TREAT (2009): no cardiovascular or renal benefit in diabetic CKD patients, but a real, nearly doubled stroke risk.

Hyperglycosylated for a longer half-life

Darbepoetin alfa is epoetin alfa's longer-acting cousin, made by the same company (Amgen) — five amino acid substitutions add two extra N-linked sugar chains to the erythropoietin backbone (five total sialic-acid-bearing chains versus three in epoetin alfa). More sialic acid reduces receptor-mediated clearance, extending the half-life to roughly 25-27 hours versus epoetin alfa's much shorter one, allowing less frequent dosing for the same anemia-correcting effect.

The TREAT trial

The FDA approved darbepoetin alfa (as Aranesp) in September 2001 for CKD-associated anemia, with a chemotherapy-induced anemia indication added in July 2002. It carries the identical class-wide boxed warning added in 2007 (see epoetin alfa for the full warning history). A large trial specific to darbepoetin, TREAT (Pfeffer et al., N Engl J Med 2009, PMID 19880844), randomized 4,038 patients with type 2 diabetes, CKD, and anemia to darbepoetin (targeting hemoglobin ~13 g/dL) or placebo with rescue dosing only if hemoglobin fell below 9. The result: no reduction in cardiovascular or renal events or death — but nearly double the risk of stroke in the darbepoetin group. This came after the 2007 warning was already in place and reinforced the same cautious-dosing message with darbepoetin-specific evidence, rather than evidence borrowed from epoetin alfa trials.

Current status

Still marketed by Amgen as Aranesp. Biosimilar competition for darbepoetin specifically is more limited than for epoetin alfa — we could not confirm a US-marketed darbepoetin biosimilar as of this review; treat any such claim with caution until verified directly.

References

  1. Pfeffer MA, Burdmann EA, Chen CY, et al. (TREAT Investigators), "A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease," N Engl J Med 2009;361(21):2019-2032, PMID 19880844.
  2. FDA approval history for Aranesp (darbepoetin alfa), September 2001 (CKD anemia); July 2002 (chemotherapy-induced anemia). Subject to the same class-wide 2007 ESA boxed warning as epoetin alfa.